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ABSTRACT
Plasma prekallikrein (PK) activation exerts both physiological and pathological
effects within the cardiovascular system and central nervous system (CNS).
Activated PK (kallikrein) controls cytokine release from human mononuclear cells
and controls both the intrinsic blood coagulation and the alternative complement
cascades. The uncontrolled activation of these cascades results in the development
of pathological pain and angioedema. Increased plasma kallikrein levels are
associated with hereditary angioedema (HAE) and myocardial infarction, whereby
kallikrein amplifies the generation of activated factor XII (FXIIa) and bradykinin (BK)
release from high molecular weight kininogen (HMWK). The primary objective of this
study was to screen natural products with anti-inflammatory properties for their
effects on the components namely HMWK, PK, FXIIa and FXIa. Terminalia chebula
fruit, Terminalia bellirica fruit, Terminalia arjuna fruit, Terminalia brownii bark,
Terminalia arjuna bark and black tea (Camellia sinensis) extracts inhibited plasma
kallikrein with IC50 values of 30, 65, 220, 240, 280 and 220 mg/ml, respectively. T.
chebula fruit, T. arjuna fruit, T. bellirica fruit, T. brownii bark, T. arjuna bark and black
tea extracts blocked plasma kallikrein on endothelial cells with IC50 values of 15, 20,
20, 80, 160 and 400 mg/ml, respectively. T. chebula fruit, T. bellirica fruit, T. arjuna
fruit, T. arjuna bark and black tea extracts blocked FXIIa activity with IC50 values of
30, 50, 190, 190 and 27 mg/ml, respectively. Arjunoglucosed II and arjunic acid
blocked FXIIa activity with IC50 values of 370 and 780 μM, respectively. T. chebula
fruit, T. arjuna fruit and black tea at 50 mg/ml did not affect endothelial cells viability.
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While red yeast rice (RYR) extract showed no inhibitory effects on plasma kallikrein,
FXIIa, FXIa and rPRCP, three pure compounds blocked FXIa activity with IC50 values
of 260, 270 and 400 μM, respectively. Overall, T. chebula fruit, T. arjuna fruit and
black tea extracts might be useful to improve symptoms of HAE, inflammation and
thrombosis. The identified inhibitors of FXIIa and FXIa could be used as a lead
compound to find potent inhibitors of these coagulation factors.
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I- INTRODUCTION

A. Kallikrein-Kinin system overview
Kallikrein-kinin system (KKS) is a complex endogenous multiprotein system. The
components of this system include the precursor kininogen, tissue and plasma
kallikreins and kinins (BK, des-Arg9 BK and BK1-5). In human, there are two types of
kininogens, high-molecular-weight kininogen (HMWK) and low-molecular-weight
kininogen (LMWK). While HMWK is synthesized in the liver and released into the
plasma, LMWK is produced locally in several tissues. Bradykinin, the major bioactive
peptide in the KKS, plays an important role in the pathological conditions including
inflammation, increased vascular permeability, vasodilation, smooth muscle
contraction, edema, pain and cell proliferation.

B. Kallikrein-Kinin system: roles of plasma Kallikrein
Human plasma kallikrein is a serine protease enzyme encoded by a single KLKB1
gene located at the q34-q35 region on the long arm of chromosome 4. Plasma
kallikrein is predominantly synthesized and secreted by the liver as a zymogen PK,
which is also known as Fletcher factor (Beaubien et al., 1991). PK is a single chain
γ-globulin polypeptide of 619 amino acids with a molecular weight of 85-88 kDa.
(Fisher C.A et al. 1982; Chung et al. 1986). Normally, 70-90% of the PK zymogen
circulates in the human blood as a complex with HMWK with stoichiometric molar
ratio 1:1 and at a range of concentration between 35-50 μg/mL (Mandle et al.1976;
Reddigari S and Kaplan AP.1989). PK can be activated into kallikrein via the actions
1

of activated factor XII (FXIIa) on negatively charged surfaces, FXIIa in fluid phase
and PRCP on endothelial cell surface (Figure 1) (Webster, 1968; Mandle, Jr. and
Kaplan, 1977; Shariat-Madar et al., 2002; Wuepper and Cochrane, 1972). PK can
be activated to kallikrein by the cleavage of the Arg371-Ile372 bond. This cleavage
forms a protein with two-subunits containing the N-terminal heavy chain and the Cterminal light chain linked by a single disulfide bond located between Cys364 and
Cys484 (Wuepper and Cochrane, 1972). While the four Apple domains (A1– A4) are
located in N-terminal heavy region, the protease domain is located in C-terminal light
chain of PK. In Kallikrein, the catalytic triad is made from His415, Asp464 and
Ser559 (van der et al., 1982; McMullen et al, 1991).
Plasma kallikrein plays crucial roles in various pathological processes of
diseases associated with inflammation through different systems in the human body
including plasma KKS (also known as contact system or intrinsic pathway) and
complement system (Figure 1). Several studies linked the activation of the contact
system in plasma to the pathogenesis of various diseases (Table 1). Plasma
kallikrein cleaves HMWK at two sites between Lys362-Arg363 and Arg371-Ser372 to
liberate BK (Webster and Pierce, 1963; Kerbiriou and Griffin, 1979) and releases the
cleaved high molecular weight kininogen (HMWKa). HMWKa binds to monocytes
and induces the production and release of the inflammatory cytokines and
chemokines that maintain the inflammatory response (Irma M. Sainz et al., 2007).
The cellular effects of kinins are mediated via two types of G-protein-coupled
receptors (GPCRs), the B1 receptors (B1R) and B2 receptors (B2R) (Leeb-Lundberg
LM et al., 2005; Marceau F et al., 1998).
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Table 1: Diseases associated with contact system (plasma KKS) activation:
Diseases

Description

References
Weiser P. et al.,

Inflammation

A localized reaction associated
with swelling, redness, warmth
and pain.

Weiser P. et al.,

Diabetic retinopathy

Systemic autoimmune disease
in which the immune system
produces antibodies in the body
attacking healthy cells.
An inherited diseases
characterized by recurrent
episodes of severe swelling.
Systemic inflammation affects
joints.
A common form of arthritis
cause a mechanical
abnormalities by affecting joins
and cartilages.
An inflammatory bowel disease
characterized by inflammation
and ulcers in the digestive tract.
A chronic disease in which the
skin cells are growing rapidly.
A diabetic eye disease caused
by the damage to the retina.

Macular edema

A swelling of the macula of the
eye.

Systemic lupus
erythematosus
Hereditary angioedema
with C1-inhibitor
deficiency
Rheumatoid arthritis
Osteoarthritis

Ulcerative colitis
Psoriasis

Sepsis
Systemic amyloidosis
Sickle cell disease
Alzheimer disease
Allergic reaction
Brain ischemia
Cirrhosis

A life-threatening blood infection
that can affect the vital organs.
A disease resulted from the
accumulation of amyloid protein
in the organs.
An inherited form of anemia that
affects hemoglobin.
A chronic brain disease affecting
memory and other mental
functions.
An overreaction resulted from
immune response to harmless
substances in the body.
Low blood supply to the brain to
meet metabolic demand.
Scarring of liver as a result from
many liver diseases.
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2010

2010
Kaufman N. et al.,
1991; Berrettini M
et al., 1986
Rahman M. M et
al., 1995
Rahman M. M et
al., 1995
Stadnicki A. et al.,
1997
Weiser P. et al.,
2010
Phipps J. A et al.,
2008; Clermont A.,
2011
Phipps J. A et al.,
2008; Clermont A.,
2011
Coppola R et al.,
1996
Maas C. et al.,
2008
Miller R. L et al.,
1983
Bergamaschini L
et al., 2001
Oschatz C. et al.,
2011
Makevnina L.G et
al., 1994
Cugno M. et al.,
1995

Complement system

Contact activation system (plasma Kinin-Kallikrein system, intrinsic pathway)

Figure 1: Roles of plasma kallikrein in hereditary angioedema through (contact
activation (plasma kallikrein-kinin), complement and fibrinolytic systems.
[Reproduced with permission from (Zuraw BL. 2008; Morgan BP. 2010), Copyright
Massachusetts Medical Society].
The B2 receptors are constitutively expressed, while the expression of B1 receptors
are induced during inflammation (Marceau F, 1995). The BK binds and activates its
constitutive B2R on endothelial cell membrane leading to an increase in the
intracellular Ca2+ levels and subsequent production of the endogenous vasodilators
nitric oxide (NO) and prostacyclin (PGI2) (Zhao et al., 2001; Hong, 1980; Palmer et
al.1987).
Plasma kallikrein is also implicated in the contact surface-mediated activation
of the intrinsic coagulation pathway (Wuepper, 1973; Saito et al., 1974; Weiss et al.,

4

1974; Colman et al., 1975; Griffin & Cochrane, 1976), in which it drives a positivefeedback loop by activating more FXII. In the complement system, plasma kallikrein
activates the alternative complement pathway (an innate component of the immune
system) and catalyzes the secondary cleavage of α-FXIIa to yield β-FXIIa, which
activates the classical complement pathway (a group of plasma proteins that
mediate the specific antibody response) (Discipio R.G. 1982; Ghebrehiwet et al.
1981). However, the activation effect produced through either of these two
complement system pathways resulted ultimately in the generation of chemotactic
mediators (C3a and C5a) and opsonins (C3b, a molecule that enhances
phagocytosis). While chemotactic mediators recruite the inflammatory cells,
opsonins initiate the membrane attack pathway to form membrane-attack complex
C5b-9 (Muller-Eberhard.1988). In addition to its complement activating properties,
plasma kallikrein can also stimulates neutrophil chemotaxis, aggregation, oxidative
metabolism and neutrophil elastase release (Kaplan et al., 1972; Schapira et
al.1982; Wachtfogel et al.1983).

C. Kallikrein-Kinin system: roles of Factor XII
Coagulation FXII is a serine protease enzyme that is produced and released by
the hepatocytes. It is encoded by the F12 gene, which has been mapped to
chromosome 5 in humans (Citarella F et al. 1988). The FXII circulates in the plasma
as a zymogen. FXII can be activated to its active form, FXIIa on the negatively
charged surfaces (Moreau ME et al. 2005). C1-INH is a major inhibitor of FXIIa and
kallikrein (Figure 1). However, insufficient C1-INH levels will cause FXIIa to initiate
the contact system leading to the local production of bradykinin (Weiss R et al.
1986). FXIIa might be implicated in hereditary angioedema (HAE) disease through
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two possible pathways. First, converting PK to kallikrein. On the surface of
endothelial cells, FXIIa can activate PK in the presence of HMWK into kallikrein,
which in turn results in the generation of BK (Kaplan AP et al. 2003; Fernando LP et
al. 2003). Second, FXIIa is a self-activating protease. This means the increase in the
FXIIa is responsible for the increased BK concentrations in HAE (Kaplan AP et al.
2003) (Figure 2). The HMWK is capable of binding and regulating several
endothelial cell surface proteins. These include cytokeratin 1, gC1qR, and urokinase
plasminogen activator receptor (uPAR). Furthermore, HMWK binds via its domain 3
and domain 5 (Joseph K et al. 1999). HMWK binding functions as a cofactor for the
activation of factor XII as well as PK (Kaplan AP et al. 2003; Mahdi F et al. 2001).

D. Hereditary angioedema (HAE)
1. General overview of HAE
Angioedema can be defined as a localized swelling beneath the skin surface in
different human body sites. It was first described by Milton in 1876. Hereditary
angioedema (HAE) is an autosomal dominant inherited disease caused by a
deficiency of the multifunctional enzyme called C1-esterase inhibitor (C1-INH). In
1882, Quincke published the first study about HAE. Later in 1888, William Osler,
studied the clinical features of HAE. In 1962, it is detected that C1-INH in the plasma
of patients with HAE (Landerman et al., 1962). In 1963, the biochemical abnormality
in the plasma of HAE patients with a deficiency of C1-INH was observed (Donaldson
and Evans, 1963). The deficiency of C1-INH results from mutations in the C1-INH
gene (SERPING1). Over 200 different mutations were identified in patients with HAE
located on chromosome 11 (11q11-q13-1). These mutations resulted either in C1INH protein depletion (type I HAE) or synthesis of an abnormal C1-INH protein (type
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II HAE). Angioedema was classified into different types based on underlying causes
such as mutations in the cases of HAE, drugs in the cases of acquired angioedema
or allergic triggers in the cases of allergic angioedema (Table 2). Commonly, two
different types of HAE are described based on the abnormality in the levels and
functions of C1-INH. Type I HAE is the most common type, which accounts for up to
85% of all HAE cases with deficiency in C1-INH plasma levels compared to the
normal values. Type II HAE accounts for up to 15% of all HAE cases with deficiency
in C1-INH plasma levels compared to the normal values.
Epidemiologic studies showed that the incidence of HAE vary from 1 in 10,000
to 1 in 150,000 individuals worldwide with no differences between races, ages and
genders (Frank MM. 2000; Talavera A. 1995). However, HAE is characterized by
intermittent attacks of localized edema and pain mainly in the extremities, face, larynx
and gastrointestinal tract without concomitant pruritus. Known triggers of HAE attacks
include anxiety, stress, trauma and illness such as the cold and flu. The most serious
attack in an HAE patient is the laryngeal attack because the swelling in this site could
resulting in airway obstruction causing a death from asphyxiation. Several plasma
proteinase inhibitors were indicated as deactivators of plasma kallikrein including C1INH, α2-macroglobulin (α2M), antithrombin III (AT III), α1-antitrypsin, and α2-antiplasmin (α2AP) (Ratnoff O. D et al., 1969; Vennerod A. M and Laake K., 1975).
C1-INH is a protease inhibitor that belongs to the serpin superfamily. It is the
major endogenous inhibitor of the plasma KKS, in which it inhibits FXIIa and Kallikrein
(Pixley et al., 1985). In 1956, Lepow was the first to find that human plasma
contained a heat sensitive factor that inhibited C1-INH activity (Lepow et al.1956). In
addition, C1-INH prevents the activation of the complements C1r and C1s (Ziccardi
R. J. and Cooper N. R., 1979). The plasma from patients with HAE showed a
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markedly decreased inhibition toward kallikrein esterolytic and amidolytic activity
compared to plasma from normal individuals, suggesting C1-INH is one of the major
endogenous inhibitors of kallikrein (Gigli I et al., 1975; Trumpi-Kalshoven et al., 1978;
Gallimore et al., 1979). In the plasma, C1-INH exhibited an inhibitory ability to
inactivate the kallikrein-mediated BK production via forming a 1:1 stoichometric
complex with kallikrein (Schapira et al., 1983a). During the HAE attack, the depletion
in the levels of functional C1-INH as a result of the mutations of its encoded gene
lead to an impaired ability to inhibit its key targets. As results, robust elevation of
plasma BK levels were generated from HMWK by kallikrein, leading to swelling,
neutrophil influx, chest pain, increased clotting, shortness of breath, and neurological
symptoms (Figure 1).

BK is responsible for most of the symptoms associated with edema in
patients experiencing acute HAE attacks. The reasons for this are the significant
increase in the levels of plasma BK, the increase in the venous blood BK from the
arms with localized HAE, and the elevations in the levels of the activated kallikrein in
induced blister fluids (Nussberger et al., 1998; Cugno et al., 1997; Shoemaker et al.,
1994; Curd et al., 1980; Nussberger et al. 2002) (Figure 2). Moreover, the levels of
PK and HMWK in patients with acute HAE attacks were decreased (Schapira et al.,
1983).
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Table 2: Overview of Hereditary Angioedema (HAE) types and treatment options

Hereditary
Angioedema
Type I (HAE-I)

Hereditary
Angioedema
Type II (HAE-II)

Hereditary
Angioedema
Type III (HAEIII)
Acquired
Angioedema
Type I (AAE-I)
Acquired
Angioedema
Type II (AAE-II)

ACE-Inhibitor

Idiopathic
NSAIDassociated
Allergic

Treatment

Description

A) Similarity of HAE type I & type II:
-Autosomal-dominant inherited (result from
mutations in C1-inhibitor gene).
-Occurring in all ages,genders & races.
-Decrease C4, normal C1q and C3 levels in
both types.
B) Dissimilarity:
-Types I & II represent; 80 to 85% and 15 to
20% of all HAE cases, respectively.
-C1-inhibitor level is decrease in type I, while it
is normal, but
does not function properly in type II.

-Unknown prevalence, but reported in women
(mainly).
- Normal C1-inhibitor, C4, C1q and C3.
-FXII gene mutations.
-Associated with pregnancy and the use of
estrogen-containing oral contraceptives.
A) Similarity of AAE type I & type II:
-Very rare.
-Immune complexes that are usually linked to
an underlying lymphoproliferative disorder
destroy the function of C1-inhibitor.
B) Dissimilarity:
Autoantibodies are present and destroy
C1-inhibitor function. There is no apparent
underlying disorder.
-Caused by ACE-Inhibitors such as captopril.
- Normal C1-inhibitor, C4, C1q and C3.
-Swelling may commence anywhere from a
few hours to years after first starting
medication
- Normal C1-inhibitor, C4, C1q and C3.
- Swelling persist > 6 week (Thyroid
dysfunction is considered).
-Angioedema without urticaria
-Not responsive to H1 antihistamine blockers.
-Normal C1-inhibitor, C4, C1q and C3.
-Swelling results from triggers such as food,
latex, venom, bee sting, cold, heat, or drug.
- Normal C1-inhibitor, C4, C1q and C3.

Options
1) Androgens such as danazol,
oxandrolone and stanozolol

Advantages
FDA-approved
Self-administration

Disadvantages
Liver toxicity, increase in
cholesterol levels & should not be
used to treat children

2) C1-inhibitor such as Cinryze™ and
Berinert®

Treating acute abdominal, facial and
laryngeal HAE attacks.

Breakthrough laryngeal or
abdominal attacks & serious
thromboembolic events,
hypersensitivity, transmitting
infectious agents

3) Bradykinin receptor antagonist such as
Firazyr®

FDA-approved
Self-administration

4) Plasma kallikrein inhibitor such as
Kalbitor®

FDA-approved
For patients 16 years of age and
older.

5) Antifibrinolytics such as tranexamic
acid

Can be used if other therapy is not
appropriate

High cost, decrease effects of
ACE inhibitors
High cost, hypersensitivity
Risks of thromboembolism,
hypotension, and cardiac
arrhythmias and low efficacy

Ref (s)
Bork K.
2012
Gandhi, P.
K et al.
2008
Bork K et
al. 2008
Banerji A
et al. 2008

Zuraw, B. L
et al. 2010
Bork K et
al. 2009

C1-INH concentrate and Icatibant can be used
Bouillet L
et al. 2009

Lymphoproliferative disorder must be targeted
Unapproved treatment options include antifibrinolytics, androgens or C1-INH concentrate

Zingale LC
et al. 2006

ACE-Inhibitors in use must be stopped or change and a bradykinin inhibitor, icatibant can be used

Weber MA
et al. 2008

Primarily antihistamines. DHEA. 1-thyroxine for thyroid dysfunction. Prednisone therapy

Avoid NSAIDs and Antifibrinolytics such as tranexamic acid and epsilon-aminocaproic acid
Antihistamines, adrenaline (epinephrine) and avoid allergic reaction triggers,

Frigas E et
al. 2006
Pérez C et
al. 2001
Douglas T.
Johnston.
2011
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Types

Figure 2: Bradykinin overproduction caused by C1-INH deficiency. Plasma BK levels
in: 1) six patients with angioedema due to Hereditary C1-Inhibitor Deficiency, 2) four
patients with angioedema related to angiotensin converting enzyme (ACE) inhibitors,
3) four patients with urticaria and angioedema that responded to antihistamines
(histaminergic angioedema). Each circle represents one patient. Solid circles denote
bradykinin levels during acute attacks of angioedema. Open circles denote levels
during the remission. The shaded area indicates the normal range of venous plasma
BK levels (0.2 to 7.1 pM). [Reproduced with permission from (Nussberger et al.
2002), Copyright Massachusetts Medical Society].
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Figure 3: Schematic representation of the mechanisms involved in the liberation of
the bradykinin (BK) from high molecular weight kininogen (HK), and subsequently
BK results in increase vascular permeability. FXI: factor XI; FXIa: activated FXI; FXII:
factor XII; FXIIa: activated factor XII; CTI: corn trypsin inhibitor; SBTI: soybean
trypsin inhibitor; DFP: Diisopropylfluorophosphate; Long polyp: long-chain
polyphosphate; rC1-inh: recombinant C1-inhibitor; IL-6: Interleukin 6; IL-1β:
Interleukin-1 beta; TNFα: tumor necrosis factor alpha; MMP2: matrix
metalloproteinase-2; MAPK: Mitogen-activated protein kinases; COX-2:
Cyclooxygenase 2; NOS: nitric oxide synthase. Red circles refer to enzymes
involved mainly in the liberation of the bradykinin (BK).

BK induced the expression of several inflammatory genes including COX-2, MMPs,
interleukins (IL-1β, IL-6) as well as chemokines (Zaczynska E et al. 2003; Terzuoli E
et al. 2014) (Figure 3). The overexpression effects of these genes via BK are
mediated through the activation of the NF-kB pathway (Terzuoli E et al. 2014). In
addition, in the airway smooth muscle cells, BK stimulates MMP-2, the enzyme that
is involved in the inflammatory processes (Zaczynska E et al. 2003; Corbel M et al.
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2002) (Figure 3). Overall, plasma kallikrein is the major BK liberator, thus it plays a
crucial role in the pathogenesis of BK-mediated diseases such as hereditary
angioedema and inflammation.

2. HAE treatment options
While plasma kallikrein is the major enzyme for liberation of BK from HMWK,
four other enzymes indirectly play roles in the liberation of BK from HMWK including:
FXIIa, activated FXI (FXIa), plasmin, and recombinant prolylcarboxypeptidase
(rPRCP) (Shariat-Madar Z et al., 2002; Kaplan AP et al., 1997; Merlini PA et al.,
2004; Motta G et al., 1998; Nishikawa K et al., 1992; Molinaro G et al., 2002).
Because plasma KKS is deeply involved in the pathogenesis HAE, the therapeutic
options were approved or designed based on their ability to inhibit this pathway.
Different options were suggested for the treatment and anaphylaxis of HAE
according to the duration of therapy including acute, short-term and long-term
therapies (Table 2). Acute treatment strategies include C1-INH (human or
recombinant) replacement therapy, plasma kallikrein inhibitor (ecallantide), or
specific bradykinin B2 receptor antagonist (icatibant). While it is not approved for the
treatment of acute attacks of HAE, the C1-INH agent Cinryze® was the first drug to
be approved by the US FDA in 2008 for chronic replacement or prophylaxis of C1INH in HAE (Cocchio and Marzella, 2009). It works by increasing C1-INH and C4 to
their normal levels. However, the bradykinin peptidomimetic Icatibant (Firazyr®), was
approved by the US FDA in 2011 as the first and only self-administered
subcutaneous drug for treating acute HAE attacks (Cicardi et al. 2010; Aberer et al.
2014). Icatibant works by decreasing the vascular permeability via inhibiting the
binding of bradykinin to its B2 recceptors, which consequently resulted in the
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reduction of vasodilation effects due to the reduction of NO and PGI2 formation. In
2009, C1-INH Berinert® and Kalbitor® were approved by the US FDA for the
treatment of acute attacks of HAE in adults, but not in children (Keating, 2009; Zuraw
et al., 2010). Ecallantide works by directly inhibiting plasma kallikrein. Several
limitations associated with Cinryze™, Berinert® and Kalbitor® therapies are reported
including high cost, risk of type I hypersensitivity reaction or anaphylaxis as well as
the risk of transmitting plasma derived infections (Lunn et al., 2010; Riedl, 2010).
Antifibrinolytics such as tranexamic acid can also be used only if other therapies are
not appropriate. Tranexamic acid works by blocking the conversion of plasminogen
to plasmin thus abolishes plasmin formation. The use of antifibrinolytics is limited
now due to their risks of thromboembolism, hypotension, and cardiac arrhythmias as
well as their low efficacy (Zuraw et al. 2008; Agostoni et al. 2004; Cicardi et al. 2010;
Dagen et al. 2010). Although fresh plasma was successfully used for the acute
treatment and prophylaxis, it is still limited due to the potential threat of worsening
HAE symptoms by its additional kinins and complement factor contents (Nzeako et
al. 2001; Agostoni et al. 1992; Galan et al. 1996; McGlinchey et al. 2000; Pekdemir
et al. 2007). Short-term prophylaxis strategies include C1-INH replacement, oral
androgens, icatibant, antifibrinolytics, and fresh plasma (Zuraw et al. 2008; Bowen et
al. 2008; Bowen et al. 2010; Marque´s et al. 2010) (Table 2).

E. Natural products as sources for new drugs
Natural products can be simply defined as any substance extracted or
isolated from nature or living organisms. Broadly, natural products can be classified
according to their sources such as plants, microbial agents, marine organisms and
animals. Natural product sources from plants have been routinely used in the
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treatment of various human diseases for thousands of years ago (Phillipson, J.D et
al, 2001). More than 70,000 plant species have been screened for their biological
activities as medicinally agents (Farnsworth, N.R et al, 1991).
Black tea (Camellia sinensis) is a species of plant in the Theaceae family.
While black tea originated in Southeast Asia, it is now cultivated worldwide to
produce commercial beverages, making it the second most popular after water
(Graham H.N et al. 1991). The major chemical constituents of black tea are
polyphenols and include catechins, theaflavins and thearubigins. The major
catechins in black tea are epigallocatechin gallate (EGCG), epigallocatechin (EGC),
epicatechin gallate (ECG), epicatechin (EC) (Li S et al. 2012). Black tea extract, and
its major constituents such as EGCG, exhibited anti-inflammatory effects by reducing
the lipopolysaccharide (LPS)-induced expression of the inflammatory cytokine
production such as IL-1β and TNF-α in human cerebral microvascular endothelial
cells (hCMECs), carrageenin-induced paw edema in rats as well as formaldehydeinduced arthritis in rats (Nag Chaudhuri A.K. et al. 2005; Jieliang Li et al. 2012). In a
recent study, black tea extract decreased the rate of blood pressure variation by
approximately 10% during the nighttime hours, suggesting its cardiovascular benefits
(Hodgson et al. 2013).
Terminalia belongs to the family Combretaceae, native to Asia includes India
and China. There are different species of Terminalia incuding T.chebula, T. bellirica,
T. arjuna and T. brownii (Figure 4). T. chebula is a deciduous tree growing up to 30
m tall with a trunk up to 1 m in diameter. It is a popular folk medicine plant that has
been traditionally used for several purposes such as an anti-inflammatory dietary
sources, antiplatelet, antioxidant, and for its cardiovascular effects (Zia-Ul-Haq M. et
al. 2012, Dolly Singh et al. 2012, Hyun-Ho Lee et al. 2015, Gautam M. K. et al.
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2013). In Ayurvedic Indian traditional medicine, T.chebula, as well as T. bellirica are
two components of triphala, a popular Ayurvedic formulation that is used for several
purposes including eye diseases, diabetes and improvement in digestion (Ayurvedic
pharmacopoeia committee, 2003). T.chebula was indicated to have a strong antiinflammatory activity in many studies. For example, the polyherbal formulation called
Aller-7, which is the combination of seven medicinal plant extracts including T.
chebula and T. bellirica extracts showed a strong anti-inflammatory effect (Pratibha
et al. 2004). In an acetic acid-induced colitis model, it was noted that T. chebula
could increase the antioxidant effects and decrease free radical formation (Gautam
M. K et al. 2013).
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Plant Scientific classification

Figure 4: Schematic representation the scientific classification of Terminalia
species used in this study and their distributions.

Red yeast rice (RYR) is the fermented product obtained after red yeast
(Monascus purpureus) is grown on rice. It had been used in China for centuries as a
food flavoring as well as a medicinal product (Wang J et al. 1997). RYR has been
used as a food colorant and preservative and in a traditional Chinese medicine. It
was described by the Pharmacopeia of the People’s Republic of China as a body
invigorative, helping in digestion, and revitalizing blood circulation (Erdogrull O et al.
2004). Several preparations of RYR are commercially available including Cholestin,
Xuezhikang and Zhibituo. These preparations were found to exhibit improvements
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on lipid profile including significant reductions of serum total cholesterol, LDLcholesterol, triglyceride (TG), and provide an increase in HDL-cholesterol (Liu JP et
al. 2006). Xuezhikang is a partially purified extract of fermented red yeast rice
(Monascus purpureus). It is composed of 13 natural statins, unsaturated fatty acids,
ergosterol, amino acids, flavonoids, alkaloid and trace elements. Xuezhikang also
exhibited lipid lowering and anti-inflammatory properties (Heber D et al. 1999).

F. Objective

Kallikrein levels are indicated to be associated with hereditary angioedema
and myocardial infarction, whereby kallikrein amplifies the generation of activated
factor XII (FXIIa) and bradykinin (BK). BK is responsible for most of the symptoms
associated with edema in patients with acute HAE attacks. Thus, BK plays a crucial
role in the pathophysiology and clinical manifestations of HAE. We hypothesized that
kallikrein inhibitors represent a novel class of drugs for reducing inflammation with a
broad spectrum of activity.
The primary objective of this study was to screen natural products known for
their anti-inflammatory and cardiovascular properties for their effects on kallikreinkinin system using amidolytic kallikrein/FXIIa assays to explore their potential
implications in the treatment of Hereditary Angioedema.
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II- EXPERIMENTAL METHODS
A. Materials
1) Reagents
Human pulmonary artery endothelial cells (HPAECs), Medium 200, low serum
growth supplement, trypsin-EDTA (ethylenediaminetetraacetic acid), Trypsinneutralizing solution (TNS), S2 cells and Hygromycin B were purchased from
Invitrogen Life Technologies (Grand Island, NY, USA). SFX-insect serum free insect
cell culture medium and DPBS (Dulbecco's phosphate-buffered saline) were
purchased from Thermo Scientific (Logan, UT, USA). Single-chain HK, human PK,
human plasma α-kallikrein and human FXIIa were purchased from Enzyme
Research Laboratories (South Bend, IN, USA). S2302; BIOPHEN CS-31 (02) was
purchased from Aniara (Mason, OH, USA). Ala-Pro-paranitroaniline (APpNA) was
purchased from Bachem (Torrance, CA, USA). Diethylaminoethyl (DEAE) cellulose
was purchased from Whatman (Fairfield, NJ, USA). Spectra/Por® Dialysis
Membrane (MWCO 6-8 kDa) was purchased from Spectrum Laboratories, Inc
(Rancho Dominguez, CA, USA), SP Sephadex 50-120 and dimethyl sulfoxide
(DMSO) were purchased from Sigma (St. Louis, MO, USA).
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Table 3: Enzymes and substrates used in the study:

Substrate
Enzyme

Name

Sequences

Kallikrein and FXIIa

S2302

H-D-Pro-Phe-Arg-p-Nitroanilide,

FXIa

S2366

Glu-Pro-Arg-p-Nitroanilide

rPRCP

APpNA

H-Ala-Pro-pNA

2) Cell Cultures
Using the endothelial cell culture, HPAEC was obtained and cultured in growth
medium 200 supplemented with low serum growth supplement according to the
manufacturer’s protocol (Invitrogen, NY) into 96 well culture plates (BRAND;
Wertheim, Germany) and incubated in a CO2 controlled incubator (5% CO2) at 37°C
overnight.
Using the Schneider (S2) cell culture, S2 cells were derived from Drosophila
melanogaster embryo. PRCP-transfected S2 cells with a plasmid were cultured in
20 mL of HyQ SFX–Insect cell culture medium (Hyclone, Utah) supplemented with
1mM Hygromycin (Invitrogen, Carlsbad, CA) in 75 cm2 tissue culture flasks (Fisher
Scientific, PA) in a temperature controlled incubator (23 ºC) (Chajkowski et al. 2011).
Once the cells were confluent, 1 flask of cells was subcultured to 3 flasks and from 3
to 10 flasks, and incubated overnight.
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B. Extraction
Black tea was extracted with deionized (DI) water (Tea was soaked in boiling
water for 15 minutes, 4 g/10 ml DI water). After 15 min it was filtered and the filtrate
was lyophilized and kept in -20 ºC freezer until fractioned and analyzed.
Terminalias extracts, red yeast rice extract and their isolated compounds
were prepared and processed by the National Center for Natural Products Research
(NCNPR) at the Univesity of Mississippi. All other natural product extracts were
prepared according to the method of Radwan MM et al. 2014.

C. Effects of natural product extracts and/or bioactive compounds on plasma
kallikrein activity in fluid phase
In this experiment the effect of the extracts or the pure compounds on the rate of
S2302 hydrolysis by kallikrein was assessed. Kallikrein (2 nM) was incubated with
increasing concentrations of the extracts (20 mg/ml to 500 mg/ml) or the pure
compounds (1 µM to 1000 µM) in the presence of 0.4 mM of the substrate (H-D-ProPhe-Arg- p-Nitroanilide, S2302) in HEPES-carbonated buffer (137 mM NaCl, 3 mM
KCl, 12 mM NaHCO3, 14.7 mM HEPES, 5.5 mM Glucose, 0.1% Gelatin, 2 mM
CaCl2, 1 mM MgCl2, 7.1 pH) for 1 hour at 37 ºC. The negative control has the same
reaction mixture except kallikrein. The positive control contains the same reaction
mixture component except the extract or the pure compound. The same increasing
concentrations of the extracts plus the substrate in HEPES-carbonated buffer
without kallikrein was used as a color control. However, the substrate hydrolysis was
assessed spectrophotometrically at 405 nm. Kallistop™ (100 μM, equivalent to 77.4
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μg/ml) was used as a reference kallikrein inhibitor and HEPES-carbonated buffer
was used for the negative control.

D. Effects of natural product extracts and/or bioactive compounds on plasma
kallikrein on endothelial cells
To determine the biological action of plant extracts or the pure compounds to inhibit
kallikrein activity on endothelial cell surface, HPAECs were grown in medium 200
supplemented with low serum growth supplement (contains fetal bovine serum,
basic fibroblast growth factor, heparin, hydrocortisone, and epidermal growth factor)
overnight in 96 well plates. Then, the cells were incubated with 1% gelatin buffer to
block the surface of the plate and the remaining cell surface to prevent nonspecific
binding of HMWK during subsequent steps. After one hour incubation period, the
cells were incubated with 30 nM HMWK for 1 hour at 37 ºC, and followed by 30 nM
of PK with increasing concentrations of the extracts (20 mg/ml to 500 mg/ml) or the
pure compounds (1 µM to 1000 µM) for 1 hour at 37 ºC. Finally, cells were incubated
with 0.5 mM of S2302 in HEPES-carbonated buffer for 1 hour at 37 ºC. Cells were
washed gently with HEPES-carbonated buffer three times between each incubation
step and the substrate hydrolysis was assessed spectrophotometrically at 405 nm.

E- Effects of natural product extracts and/or bioactive compounds on FXIIa
activity in fluid phase
Next, investigations were peformed to determine the biological action of the plant
extracts and pure compounds on FXIIa. Increasing concentrations of the extracts (20
mg/ml to 500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with
17 nM of FXIIa and 0.4 mM of the substrate (H-D-Pro-Phe-Arg- p-Nitroanilide,
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S2302) in HEPES-carbonated buffer at 37 ºC for 1 hour. The negative control had
0.4 mM of S2302 in HEPES-carbonated buffer. The positive control had 0.4 mM of
S2302 plus 17 nM of FXIIa without the extract or the pure compound. The color
controls have the same increasing concentrations of the extracts plus 0.4 mM of
S2302 in HEPES-carbonated buffer without FXIIa enzyme. Then the hydrolysis was
measured at wavelength 405 nm using absorbance plate reader. Corn trypsin
inhibitor (9 μM, equivalent to 126 μg/ml) was used as a reference FXIIa inhibitor.

F- Effects of natural product extracts and/or bioactive compounds on FXIIainduce HPAEC migration
After plating 5,000 of HPAECs per well, the cells were incubated overnight to
achieve 90 % confluence. HPAEC monolayers were scratched using 200 µL pipette
tip, and serum-containing media was added to each well. Reference points near the
scratch were marked using the marker. Wells were washed with 100 µL of DPBS
(Dulbecco's phosphate-buffered saline) buffer two times to remove the floating cells
resulted from the scratch. First, to determine the magnitude of the pharmacological
effect, cells were incubated with various concentrations of the plant extracts.
However, 100 µL of growth medium in the presence of increasing concentrations of
the plant extract was added to the wells. Other types of treatment include the
following: 1) 100 µl of growth medium per well were used as positive control, 2) 240
nM of FXIIa in 100 µl total volume of growth medium per well were used to induced
HPAECs migration, 3) selected plant extract concentrations were added to 100 µl
total volume of growth medium per well in the absence of 240 nM FXIIa, 4) selected
plant extract concentrations were added to 100 µl total volume of growth medium per
well in the presence of 240 nM FXIIa. Images of the wells were taken at 0 hr with a
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phase contrast microscope. After 24 hrs, growth medium of all the wells was
decanted and wells were washed with 100 µL DBPS two times, 100 µL of cold
methanol were added to each well and incubated at 4 °C for 5 mins. Next, the cold
methanol was decanted and 70 µL of diluted crystal violet dye (0.1%) in DBPS was
added to each well and incubated for 30 minutes at room temperature. The loose
from the cells dye was washed by the water and the wells allowed to dry for 1 hr at
room temperature. Serial images of the reference points at the beginning and during
the migration close to the scratch (wound) area were taken. The effects of the plant
extract on the migration rate were quantified by comparing the images using imageJ.
Each group had wells in triplicates, and each experiment was repeated 3 times.

G- Effects of natural product extracts and/or bioactive compounds on rPRCP
activity in fluid phase
1- Transfected Drosophila Schneider (S2) cell culture
The enzyme rPRCP was purified form Schneider (S2) cells in which S2 cells were
derived from Drosophila melanogaster embryo. S2 cells were transfected previously
with a plasmid carrying the human PRCP gene, as described previously (ShariatMadar Z et al. 2004). S2 cells were cultured in 20 mL of HyQ SFX–Insect cell culture
medium (Hyclone, UT) and hygromycin B (Invitrogen, CA) were added in a
concentration of 1 mM to facilitate the selective growth of cells with the rPRCP1
plasmid in 75 cm2 tissue culture flasks (Fisher Scientific, PA) at 23 ºC in atmospheric
air. Once the cells were confluent, 1 flask of cells was subcultured to 3 flasks and
from 3 flasks to 10 flasks and incubated at 23 ºC in atmospheric air.
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2- rPRCP purification from transfected S2 cells
2.1 S2 cells induction
In the induction step, the suspended S2 cells from 12 flasks were transferred to
several 50 mL polypropylenecentrifuge tubes and centrifuged for 10 minutes at 350x
g at 23 °C. The cell pellet was resuspended in the induction medium, HyQ SFXInsect cell culture medium (Hyclone, UT) in which 1 mM hygromycin B (Invitrogen,
CA) and 0.66 mM CuSO4 (CuSO4 induced human PRCP gene through
metallothionein gene to express rPRCP (Lys46-His496) protein into the supernatant)
was added and incubated in dark for 48 hours at 23 °C on a shaker with circular or
rocker shaking motion for gentle mixing and oxygenating the cells.

2.2 Dialysis I
Following 48 hours of incubation, the supernatant was collected from the cell
suspensions via centrifugation for 10 min at 350x g at 23 °C. Then the supernatant
was transferred to spectra/por 1 dialysis membrane (Spectrum Laboratories, CA).
This tubing membrane has 6-8 kDa molecular weights cut off. The membrane was
prepared for dialysis according to the manufacturer's instructions. The supernatant
was dialyzed in 4 liters of 1x Tris Buffer (10 mM Tris, 25 mM NaCl, 0.5 mM EDTA,
0.5 mM β-mercaptoethanol; pH 7.1) overnight at 4 °C with two times buffer changes
after 4 to 6 hrs.

2.3 Anion exchange chromatography
In anion exchange chromatography, ten grams of diethylaminoethyl (DEAE)
cellulose resin (Whatman, AZ) was soaked in 40 ml of 1x Tris Buffer (10 mM Tris, 25
mM NaCl, 0.5 mM EDTA, 0.5 mM β-mercaptoethanol; pH 7.1) and the buffer was
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changed once after 30 mins. A DEAE-cellulose solution was added to column (3.5
cm inner diameter X 25 cm length) and then packed and equilibrated with 3 times
the bed volume (20 to 22 mL) of 1x Tris buffer. The dialysate was loaded into the
column. The column was subsequently washed with 3 times the bed volume of 1x
Tris buffer.

2.4 Dialysis II
The flow-through from the sample and washing steps were pooled and transferred
into dialysis tubing membrane. The sample was dialyzed in 1x CH3COONa buffer
(10 mM CH3COONa, 0.5 mM EDTA, 0.5 mM β-Mercaptoethanol; pH 4.8) overnight
in 4°C with two times buffer changes after 4 to 6 hrs.

2.5 Cation exchange chromatography
In the cation excharge chromatography, 0.45 g of sephadex-SP 150-20 column resin
(Sigma-Aldrich Co., MO) was soaked in 40 ml and equilibrated in 1x CH3COONa
buffer (10 mM sodium acetate trihydrate, 0.5 mM EDTA, 0.5 mM β-mercaptoethanol,
4.8 pH) for one hour. The buffer was changed once after 30 minutes. The sephadexSP solution was added to a column (1.5 cm inner diameter X 25 cm length) and then
packed and equilibrated with 3 times the bed volume (30 to 35 mL) of 1x
CH3COONa buffer at 4°C using a cold room. The dialysate was loaded into the
column and the column was washed with 1x CH3COONa buffer. rPRCP adsorbs to
the column. The bound rPRCP protein was recovered from the column by eluting
with 0.2 M KCl (in 1x CH3COONa) (in a volume equivalent to 3 times the bed
volume). The rPRCP obtained was stored at 4 °C to be used in the activity assay.
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3- rPRCP activity assay
To determine the inhibitory effects, increasing concentrations of the extracts (20
mg/ml to 500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with
the purified rPRCP (30 µg/ml) and 0.5 mM of the substrate H-Ala-Pro-pNA (APpNA)
in HEPES-carbonated buffer for 1 hour at 37 ºC. The negative control has only 0.5
mM of APpNA in HEPES-carbonated buffer. The positive control has 0.5 mM of
APpNA plus an appropriate volume of the purified rPRCP without the extract. The
color controls have the same increasing concentrations of the extract plus 0.5 mM of
APpNA in HEPES-carbonated buffer without rPRCP. The substrate hydrolysis was
assessed spectrophotometrically at 405 nm. Z-Pro-Prolinal (10 mM, equivalent to 3.3
mg/ml) was used as a reference rPRCP inhibitor.

H. Effects of natural product extracts and/or bioactive compounds on FXIa
activity in fluid phase
To determine the pharmacological effects of the plant extracts and the pure
compounds to inhibit FXIa, increasing concentrations of the extracts (20 mg/ml to
500 mg/ml) or the pure compounds (1 µM to 1000 µM) were incubated with 2 nM of
FXIa and 0.291 mM of the substrate (Glu-Pro-Arg-p-Nitroanilide, S2366) in HEPEScarbonated buffer for 1 hour at 37 ºC. Then the substrate hydrolysis was assessed
spectrophotometrically at 405 nm.

I. Effects of natural product extracts and/or bioactive compounds on FXIa
activity on HPAEC
To determine the pharmacological effects of the plant extracts and the pure
compounds to inhibit the production of FXIa on the surface of endothelial cells,
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HPAECs were grown in medium 200 supplemented with low serum growth
supplement overnight at 37 oC in 96 well plates. The cells were washed three times
with HEPES-carbonated buffer and blocked with 1% gelatin for 1 hour at 37 oC to
prevent non-specific binding. After three times washing with HEPES-carbonated
buffer, HPAEC were incubated with 80 nM of HK for 1 hour at 37 oC. At the end of
incubation, cells were washed three times with HEPES-carbonated buffer to remove
the unbound HK and then treated with 40 nM of FXI. After incubation for one hour at
37 oC, cells were washed three times with HEPES-carbonated buffer and 0.5 mM
S2366 (Glu-Pro-Arg-pNA·HCl) in HEPES-carbonated buffer was added to determine
the effects on FXIa activity. Substrate hydrolysis was allowed to proceed for 1 hour
at 37 oC. FXIa activity was measured as the change in UV absorbance at 405 nm,
using BioTek ELx800 Absorbance Microplate Reader.

J. MTT cell viability assay
Cell viability was determined by thiazolyl blue tetrazolium bromide (MTT) colorimetric
assay. First, 25,000 cells per well of HPAECs were seeded in 96-well culture plates
cultivated and incubated overnight at 37 °C. Following the addition of
arjunoglucoside-II for 1 hour, 20 μl of filtered MTT solution containing 5 mg/ml MTT
in serum free medium was added to each well. After 4 h of incubation at 37 °C, the
medium was aspirated and the cells were lysed by the addition of 150 μL per well
MTT solvent containing 4 mM HCl and 0.1% Nondet P-40 (NP40) in 100%
isopropanol. Plates were covered with aluminium foil and placed on an orbital shaker
for 15 minutes at room temperature. The optical density (OP) of each sample was
measured in a microplate reader using a reference wavelength of 570 nm with
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background subtraction at 690 nm. Each group had three wells and each experiment
was replicated 3 times.

K. Statistical analysis
The mean ± SEMs from the bioassays of plasma kallikrein, rPRCP, and FXlla, FXIa
and kallikrein formed on cells were analyzed with nonlinear regression in GraphPad
Prism 6.0. GraphPad Software, Inc., USA. Experiments were performed at least
three times in duplicate or triplicate. Data was analyzed using one-way analysis of
variance (ANOVA). For all comparisons, statistical significance was defined as *P ≤
0.05, **P ≤ 0.01, ***P ≤ 0.001 or ****P ≤ 0.0001.
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III-RESULTS
A) Effects of natural product extracts and/or their bioactive compounds on
plasma kallikrein activity:
Plasma kallikrein plays an important role in the pathogenesis of hereditary
angioedema in which the levels of plasma kallikrein-mediated bradykinin production
is increased due to the depletion in the levels of its major endogenous, C1-INH. So,
in order to develop a safe and effective plasma kallikrein inhibitor that could inhibit
kallikrein-mediated generation of BK from HMWK, we have screened several natural
plant extracts listed in (Table 4) for their effects on enzymes involved either directly
such as plasma kallikrein or indirectly such as FXIIa, and rPRCP in the liberation of
BK from HMWK. These natural products were selected based on their antiinflammatory and cardiovascular effects shown in the literature as well as their safety
and availability (Table 3).
Table 4: Screened natural products and their reported health benefits.
Plants
Anise
Basil

Species
Pimpinella
anisum
Ocimum
basilicum

Part
used

Health benefits

Fruit

Antiinﬂammatory and antioxidant

Herb

Antiinflammatory and antioxidant

Black pepper

Piper
nigrum

Fruit

Antioxidant, hypolipidemic effect, antiinﬂammatory

Cardamon

Elettaria
cardamomum

Fruit

Antioxidant, antihypertensive and antiplatelet
aggregation, antiinﬂammatory
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Cayenne
pepper

Capsicum
annuum

Fruit

Antiinﬂammatory, decrease cholesterol levels
and Antioxidant

Cinnamon

Cinnamomu
m cassia

Bark

Antioxidants, antiinflammatory, reduce blood
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reduced peripheral vascular resistance and
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Clove

Syzygium
aromaticum

Fruit
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effect and antihypertensive

Coriander

Coriandrum
sativum

Herb

Hypolipidemic effect, antiplatelet activity,
antiinﬂammatory

Cumin

Cuminum
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Fruit

Hypolipidemic effect, antihypertensive,
antioxidant and Antiinflammatory

Seed

Antioxidant

Fruit

Antiinﬂammatory and antioxidant

Fruit

Antiinflammatory and antioxidant

Garlic

Allium
sativum

Seed

Decrease lipid synthesis, blood pressure and
platelet aggregation and antioxidant

Ginger
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officinale

Rhizome
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vessels, stimulate blood flow and relieve pain

Henna
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Marjoram
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majorana

Herb

Antiinflammatory and antioxidant

Herb

Antiinflammatory

Fruit

Antiinflammatory and antioxidant

Herb

Antiinflammatory and antioxidant

Fruit

Antiinflammatory

Poppy seed
Dill
Fennel

Mentha
Nutmeg
Oregon

Papaver
somniferum
Anethum
graveolens
Foeniculum
vulgare

Mentha
spicata
Myristica
fragrans
Origanum
vulgare

Paprika
Rosemary

Rosmarinus
officinalis

Herb

Antiinflammatory and antioxidant

Thyme

Thymus
vulgaris

Herb

Antiinflammatory and antioxidant

Tea

Camellia
sinensis

Herb

Preventive effect against atherosclerosis and
coronary heart disease, antiinﬂammatory,
reduce the risk of high blood pressure

Fruit and
bark

Antihypertensive, Antioxidant, effective in
heart diseases

Fruit

Anti-inflammatory and antinociceptive

Bark

Anti-inflammatory of arjunic acid (terminaia
brownii constituent)

Terminalia

Terminalia
arjuna
Terminalia
bellirica
Terminalia
brownii
Terminalia
chebula

Red yeast
rice

Fruit

Decrease cholesterol levels, cardiotonic
effect, antiplatelet effect, antioxidant, antiinflammatory

Red
fermente
d rice

Anti-inflammatory, hypolipidemic effects and
reduced the cardiovascular outcomes
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To determine their pharmacological effects on plasma kallikrein activity, we
have screened thirty plant extracts on kallikrein activity at a selected concentration
200 mg/ml and accordingly continue our study on the extracts showing promising
effects (Figure 5).
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Figure 5: Effect of natural product extracts on plasma kallikrein activity. 200
mg/ml of thirty natural product extracts were incubated with Kallikrein (2 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments. [*P ≤
0.05, ***P ≤ 0.001, ****P ≤ 0.0001 compare to control]
T. arjuna fruit and T. arjuna bark were tested at 200 mg/ml. While T. arjuna
fruit exhibited a significant inhibitory effect on plasma kallikrein by 45%, its bark
extract showed no effect (Figure 5). T. bellirica fruit, T. brownii bark and T. chebula
fruit methanol extracts significantly blocked the liberation of paranitroaniline from
S2302 by plasma kallikrein by 65%, 45% and 85%, respectively (Figure 5). Black
tea aqueous extract was found to have a significant anti-inflammatory effect
(Chatterjee P et al. 2012). Additionally, black tea is one of the most common
beverage worldwide (Graham H.N et al. 1991; Monika Mueller. 2010). Investigations
indicated that black tea aqueous extract significantly inhibited the hydrolysis of
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S2302 (0.4 mM) by plasma kallikrein (2 nM) by 55%. At 200 mg/ml, methanol
extracts of some other natural products also significantly inhibited plasma kallikrein
activity; black pepper (35%) and cardamom (30%), cayenne pepper (15%), clove
(15%), cumin (25%), poppy seed (50%), dill (20%), garlic (15%), ginger (17%) and
rosemary (17%) (Figure 5). Red yeast rice extract was also tested on plasma
kallikrein activity and showed no effect (Figure 5). Although the majority of the plant
extracts inhibited kallikrein to various extents, we decided to continue evaluating the
methanol extracts of all Terminalia species as well as the aqueous extract of black
tea.
The methanol extracts of T. arjuna fruit and T. arjuna bark inhibited the
hydrolysis of S2302 by plasma kallikrein with IC50 values of 220 mg/ml and 280

% K a llik r e in a c t iv ity

mg/ml, respectively (Figures 6 & 7).
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Figure 6: Effect of Terminalia arjuna fruit extract on plasma kallikrein activity.
Increasing concentrations of T. arjuna fruit extract were incubated with Kallikrein (2
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302
was detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 7: Effect of Terminalia arjuna bark extract on plasma kallikrein activity.
Increasing concentrations of T. arjuna bark extract were incubated with Kallikrein (2
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302
was detected at 405 nm. Data represent the mean ± SEM of three experiments.
The methanol extracts of T. bellirica fruit (Figure 8), T. brownii bark (Figure 9)
and T. chebula fruit (Figure 10) showed inhibitory effects on the hydrolysis of S2302
by plasma kallikrein with IC50 values of 65 mg/ml, 240 mg/ml and 30 mg/ml,
respectively.

Figure 8: Effect of Terminalia bellirica fruit extract on plasma kallikrein activity.
Increasing concentrations of T. bellirica fruit extract were incubated with Kallikrein (2
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 9: Effect of Terminalia brownii bark extract on plasma kallikrein activity.
Increasing concentrations of T. brownii bark extract were incubated with Kallikrein (2
nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302
was detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 10: Effect of Terminalia chebula fruit extract on plasma kallikrein
activity. Increasing concentrations of T. chebula fruit extract were incubated with
Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
Black tea aqueous extract blocked the activity of plasma kallikrein in fluid
phase with an IC50 value of 220 mg/ml (Figure 11).
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Figure 11: Effect of black tea aqueous extract on plasma kallikrein activity.
Increasing concentrations of black tea aqueous extract were incubated with
Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.

We have also tested black tea major compounds including epigallocatechin
gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin
(EC), caffeine and quercetin on plasma kallikrein activity in fluid phase, but all
showed no effect (Figure 32).

B) Effects of natural product extracts and/or their bioactive compounds on
plasma kallikrein generation on HPAEC:
Plasma kallikrein can be generated from the activation of PK on the
endothelial cell surface via two stimuli, activated factor XII (FXIIa) on negatively
charged surfaces and prolylcarboxypeptidase (PRCP) (Figure 1) (Webster, 1968;
Mandle, Jr. and Kaplan, 1977; Shariat-Madar et al., 2002; Wuepper and Cochrane,
1972). Thus, we aimed to test the efffects of the plant extracts and the pure
compounds on kallikrein produced as a result of PK activation on endothelial cell
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surface. HPAECs were treated with 30 nM HMWK followed by 30 nM PK in the
presence of increasing concentrations of the extracts or the compounds.
Both T. arjuna fruit and T. arjuna bark inhibited the hydrolysis of S2302 by kallikrein
produced on HPAEC with IC50 values of 20 and 160 mg/ml, respectively (Figures 12

% K a llik r e in a c t iv it y o n H P A E C

& 13).
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Figure 12: Effect of Terminalia arjuna fruit extract on plasma kallikrein formed
on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37
°C. Then the cells were incubated with PK (30 nM) in the presence of increasing
concentrations of T. arjuna fruit extract for 1 hr at 37 °C. Next, the cells were
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed
S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 13: Effect of Terminalia arjuna bark extract on plasma kallikrein formed
on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37
°C. Then the cells were incubated with PK (30 nM) in the presence of increasing
concentrations of T. arjuna bark extract for 1 hr at 37 °C. Next, the cells were
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed
S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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T. bellirica fruit (Figure 14), T. brownii bark (Figure 15) and T. chebula fruit
(Figure 16) extracts also inhibited the generation of kallikrein on the endothelial cells

% K a llik r e in a c t iv it y o n H P A E C

with IC50 values of 20, 80 and 15 mg/ml, respectively.
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Figure 14: Effect of Terminalia bellirica fruit extract on plasma kallikrein
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of
increasing concentrations of T. bellirica fruit extract for 1 hr at 37 °C. Next, the cells
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 15: Effect of Terminalia brownii bark extract on plasma kallikrein
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of
increasing concentrations of T. brownii bark extract for 1 hr at 37 °C. Next, the cells
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 16: Effect of Terminalia chebula fruit extract on plasma kallikrein
formed on endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr
at 37 °C. Then the cells were incubated with PK (30 nM) in the presence of
increasing concentrations of T. chebula fruit extract for 1 hr at 37 °C. Next, the cells
were incubated with S2302 (0.5 mM) for 1 hr at 37 °C 1 hr. The absorbance of
hydrolyzed S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.

We have tested the activity of two Terminalia isolated compounds on PK
activation on HMWK bound to HPAECs. Arjunoglucoside II and arjunic acid inhibited
the generation of kallikrein in a concentration dependent manner with IC50 values of
300 and 240 μM, respectively (Figures 17 & 18).
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Figure 17: Effect of arjunoglucoside II on plasma kallikrein formed on
endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 °C.
Then the cells were incubated with PK (30 nM) in the presence of increasing
concentrations of arjunoglucoside II for 1 hr at 37 °C. Next, the cells were incubated
with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 18: Effect of arjunic acid on plasma kallikrein formed on endothelial
cells. HPAECs were incubated with HMWK (30 nM) at 37 °C for 1 hr. Then the cells
were incubated with PK (30 nM) in the presence of increasing concentrations of
arjunic acid for 1 hr at 37 °C. Next, the cells were incubated with S2302 (0.5 mM) for
1 hr at 37 °C. The absorbance of hydrolyzed S2302 was detected at 405 nm. Data
represent the mean ± SEM of three experiments.
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We tested the effect of black tea aqueous extract on the generation of
kallikrein on endothelial cells and indicated that black tea blocked kallikrein with an

% Kallikrein Activity on HPAEC

IC50 value of 400 mg/ml (Figure 19).
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Figure 19: Effect of black tea aqueous extract on plasma kallikrein formed on
endothelial cells. HPAECs were incubated with HMWK (30 nM) for 1 hr at 37 °C.
Then the cells were incubated with PK (30 nM) in the presence of increasing
concentrations of black tea aqueous extract for 1 hr at 37 °C. Next, the cells were
incubated with S2302 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed
S2302 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.

C) Effects of natural product extracts and/or their bioactive compounds on
FXIIa activity:
Because FXIIa can activate PK to kallikrein, which in turn results in the
generation of BK (Kaplan AP et al. 2003; Fernando LP et al. 2003), we aimed to
determine whether Terminalias and black tea extracts could inhibit FXIIa activity.
The results indicated that T. arjuna fruit (Figure 20), T. arjuna bark (Figure 21), T.
bellirica fruit (Figure 22) and T. chebula fruit (Figure 23) extracts blocked FXIIa
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activity with IC50 values of 190, 190, 50 and 30 mg/ml, respectively. T. brownii bark
extract showed a minor inhibitory activity in amidolytic system. The extract from T.
brownii bark had the least inhibitory effect on FXIIa activity. It inhibited FXIIa by 27%
at highest concentration (Figure 24).

Figure 20: Effect of Terminalia arjuna fruit extract on FXIIa activity. Increasing
concentrations of T. arjuna fruit extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.

Figure 21: Effect of Terminalia arjuna bark extract on FXIIa activity. Increasing
concentrations of T. arjuna bark extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 22: Effect of Terminalia bellirica fruit extract on FXIIa activity. Increasing
concentrations of T. bellirica fruit extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.

% F X IIa a c t iv it y

100

75

50

25

0
0

50

100

150

200

T e r m in a lia C h e b u la f r u it e x tr a c t ( m g /m l)

Figure 23: Effect of Terminalia chebula fruit extract on FXIIa activity. Increasing
concentrations of T. chebula fruit extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 24: Effect of Terminalia brownii bark extract on FXIIa activity. Increasing
concentrations of T. brownii bark extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 25: Effect of black tea aqueous extract on FXIIa activity. Increasing
concentrations of black tea aqueous extract were incubated with FXIIa (17 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Black tea aqueous extract blocked the activity of FXIIa with an IC50 value of 27
mg/ml (Figure 25). Black tea major compounds including epigallocatechin gallate
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC),
caffeine and quercetin were ineffective in inhibiting FXIIa activity (Figure 32).

On the effects of Terminalia pure compounds, among all tested compounds,
arjunoglucoside II and arjunic acid showed inhibitory effects with IC50 values of 370
and 780 µM, respectively (Figures 26 & 27).
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Figure 26: Effect of arjunoglucoside II on FXIIa activity. Increasing
concentrations of arjunoglucoside II were incubated with FXIIa (17 nM) and S2302
(0.4 mM) for 1 hr at 37 °C (structure is shown). The absorbance of hydrolyzed S2302
was detected at 405 nm. Data represent the mean ± SEM of three experiments.
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Figure 27: Effect of arjunic acid on FXIIa activity. Increasing concentrations of
arjunic acid were incubated with FXIIa (17 nM) and S2302 (0.4 mM) for 1 hr at 37
°C. The absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent
the mean ± SEM of three experiments.

D) Effects of natural product extracts and/or their bioactive compounds on
recombinant PRCP activity:
Because PRCP is also an activator of PK to kallikrein on the endothelial cells,
we aimed to determine whether Terminalias and black tea extracts could inhibit
PRCP activity. Using recombinant human PRCP (rPRCP), we tested the methanol
extracts of all Terminalia species as well as the aqueous extract of black tea on
rPRCP activity. As described above in methods, increasing concentrations of
extracts were incubated with rPRCP (30 µg/ml) and the substrate APpNA (0.5 mM).
T. arjuna fruit, T. chebula fruit and T. brownii bark extracts blocked the release of
paranitroaniline from APpNA by rPRCP with an IC50 values of 150, 120 and 280
mg/ml, respectively (Figures 28, 29 & 30). T. arjuna bark and T. bellirica fruit did not
inhibit rPRCP activtity.
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Figure 28: Effect of Terminalia arjuna fruit extract on rPRCP activity. Increasing
concentrations of T. arjuna fruit extract were incubated with rPRCP (30 µg/ml) and
the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of paranitronilide
was detected at 405 nm. Data represent the mean ± SEM of three experiments.

Figure 29: Effect of Terminalia chebula fruit extract on rPRCP activity.
Increasing concentrations of T. chebula fruit extract were incubated with rPRCP (30
µg/ml) and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 30: Effect of Terminalia brownii bark extract on rPRCP activity.
Increasing concentrations of T. brownii bark were incubated with rPRCP (30 µg/ml)
and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
Black tea aqueous extract inhibited rPRCP with IC50 value of 160 mg/ml
(Figure 31). Black tea major compounds showed no effect on rPRCP activity
(Figure 32).
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Figure 31: Effect of black tea aqueous extract on rPRCP activity. Increasing
concentrations of black tea aqueous extract were incubated with rPRCP (30 µg/ml)
and the substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of
paranitronilide was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 32: Effect of black tea pure compounds on plasma kallikrein, FXIIa and
rPRCP activities. Panel.A Increasing concentrations of epigallocatechin gallate
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin (EC)
were incubated with Kallikrein (2 nM) and S2302 (0.4 mM) for 1 hr at 37 °C. The
absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent the mean
± SEM of three experiments. Panel.B Increasing concentrations of EGCG, EGC, ECG
and EC were incubated with FXIIa (17 nM) and S2302 (0.4 mM) for 1 hr at 37 °C.
The absorbance of hydrolyzed S2302 was detected at 405 nm. Data represent the
mean ± SEM of three experiments. Panel.C Increasing concentrations of EGCG,
EGC, ECG and EC were incubated with rPRCP (30 µg/ml) and the substrate APpNA
(0.5 mM) for 1 hr at 37 °C. The absorbance of paranitronilide was detected at 405
nm. Data represent the mean ± SEM of three experiments.
E) Effects of natural product extracts and/or their bioactive compounds on
HPAEC viability using the MTT assay:
To test weather the inhibitory effects of tested extracts on the generation of
plasma kallikrein from PK are not from their effects on HPAEC viability, we
determined if these extracts were directly toxic to the endothelial cells using the MTT
assay in which the yellow tetrazole is reduced to purple formazan only in living cells.
While T. arjuna fruit showed no significant effects on HPAECs viability (Figure 33),
T. arjuna bark was significantly reduced HPAECs viability by 40% at concentrations
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equal to or greater than 30 mg/ml (Figure 34).
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Figure 33: Effect of Terminalia arjuna fruit extract on HPAEC viability using the
MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by T. arjuna fruit extract using the MTT assay. The wells containing
HPAECs were treated T. arjuna fruit extract for its effect on cell viability, and the wells
containing only a complete growth medium were used as a control. Data represent
the mean ± SEM of three experiments.
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Figure 34: Effect of Terminalia arjuna bark extract on HPAEC viability using
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by T. arjuna bark extract using the MTT assay. The wells containing
HPAECs were treated T. arjuna bark extract for its effect on cell viability, and the
wells containing only a complete growth medium were used as a control. Data
represent the mean ± SEM of three experiments. [****P ≤ 0.0001 compare to %
control].
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T. bellirica fruit and T. brownii bark were significantly toxic to HPAECs in which
T. bellirica fruit exhibited its cytotoxic effect in dose-dependent manner (Figure 35)
and T. brownii bark reduced HPAECs viability at concentartions equal to or greater
than 20 mg/ml by approximately 40% indicating its toxic effect on endothelial cells
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(Figure 36).
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Figure 35: Effect of Terminalia bellirica fruit extract on HPAEC viability using
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by T. bellirica fruit extract using the MTT assay. The wells
containing HPAECs were treated T. bellirica fruit extract for its effect on cell viability,
and the wells containing only a complete growth medium were used as a control.
Data represent the mean ± SEM of three experiments. [*P ≤ 0.05, ***P ≤ 0.001, ****P
≤ 0.0001 compare to % control]
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Figure 36: Effect of Terminalia brownii bark extract on HPAEC viability using
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by T. brownii bark extract using the MTT assay. The wells
containing HPAECs were treated T. brownii bark extract for its effect on cell viability,
and the wells containing only a complete growth medium were used as a control.
Data represent the mean ± SEM of three experiments. [**P ≤ 0.01, ***P ≤ 0.001
compare to % control]
Interestingly, T. chebula fruit extract exhibited no effects on HPAECs viability
at concentrations up to 500 mg/ml (Figure 37). Among all Terminalias, the results of
T. chebula fruit extract suggested that the inhibitory effect of the methanol extract of
T. chebula fruit on kallikrein produced on endothelial cell surface is not due to the
cytotoxicity to endothelial cells. Thus, methanol extract of T. chebula fruit might be
considered a safe natural supplement inhibitor of kallikrein.
We have tested the two compounds from Terminalia that showed effects on
the generation of kalikrein on HPAECs to explore their effects on HPAECs viability.
We indicated that arjunoglucoside II significantly deceased the viability of cells only
at high dose up to 1 mM (Figure 38), but arjunic acid induced cellular toxicity at
concentartions equal to or greater than 300 μM (Figure 39).
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Figure 37: Effect of Terminalia chebula fruit extract on HPAEC viability using
the MTT assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by T. chebula fruit extract using the MTT assay. The wells
containing HPAECs were treated T. chebula fruit extract for its effect on cell viability,
and the wells containing only a complete growth medium were used as a control.
Data represent the mean ± SEM of three experiments.

A r ju n o g lu c o s id e II

Figure 38: Effect of arjunoglucoside II on HPAEC viability using the MTT
assay. Bar diagrams showing the results of HPAECs viability (% of control).
HPAECs treated by arjunoglucoside II using the MTT assay. The wells containing
HPAECs were treated arjunoglucoside II for its effect on cell viability, and the wells
containing only a complete growth medium were used as a control. Data represent
the mean ± SEM of three experiments. [*P ≤ 0.05 compare to % control]
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Figure 39: Effect of arjunic acid on HPAEC viability using the MTT assay. Bar
diagrams showing the results of HPAECs viability (% of control). HPAECs treated by
arjunic acid using the MTT assay. The wells containing HPAECs were treated arjunic
acid for its effect on cell viability, and the wells containing only a complete growth
medium were used as a control. Data represent the mean ± SEM of three
experiments. [*P ≤ 0.05, ****P ≤ 0.0001 compare to % control]

The aqueous extract of black tea had no significant effect on HPAECs viability
after 1 hr treatment (Figure 40A). However, the aqueous extract of black tea
induced a higher cytotoxicity on HPAECs compare to the control after 24 hours of
incubation at 37 °C. The results indicated that 100 mg/ml black tea aqueous extract
decreased cellular viability by 80% (Figure 40B).
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Figure 40: Effect of black tea aqueous extract (1hr & 24 hrs treatments) on
HPAEC viability using the MTT assay. Bar diagrams showing the results of
HPAECs viability (% of control). HPAECs treated by black tea aqueous extract for 1
hr or 24 hrs using the MTT assay. The wells containing HPAECs were treated with
black tea aqueous extract for its effect on cell viability, and the wells containing only
a complete growth medium were used as a control. Data represent the mean ± SEM
of three experiments. [****P ≤ 0.0001 compare to % control].
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F) Effects of the aqueous extract of black tea on FXIIa-induced HPAEC
migration:

To confirm the inhibitory effect exhibited by the aqueous extract of black tea on
FXIIa activity, we tested the effect of the aqueous extract of black tea on FXIIainduced HPAEC migration. Evidence suggests that FXII stimulates the proliferation
of endothelial cell (Gretchen A. LaRusch et al. 2010). FXII was found to significantly
affect cell migration in the low nanomolar range (60 to 240 nM). Contact of plasma
with the negatively charged surfaces results in binding and autoactivation of FXII to
FXIIa (Moreau ME et al. 2005).
To determine at which concentrations the aqueous extract of black tea itself
can inhibit HPAEC migration, we investigated the concentration-dependent effects of
the aqueous extract of black tea ranging from 5 to 100 mg/ml. The aqueous extract
of black tea significantly inhibited HPAECs migration only at 100 mg/ml (Figure 41).
Since the aqueous extract of black tea did not inhibit HPAECs migration at
concentrations up to 50 mg/ml, we assessed the effect of 50 mg/ml black tea
aqueous extract on FXIIa-induced HPAEC migration. We found that 50 mg/ml was
significantly inhibited FXIIa-induce HPAEC migration confirming our previous finding
on the effect of black tea aqueous extract on FXIIa activity in fluid phase (Figure 42).
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Figure 41: Effects of black tea aqueous extract on HPAEC migration. HPAECs
were seeded in a 96-well plate and incubated overnight at 37 °C to achieve
confluence. Then a denuded area was created with a pipette tip. Next, the plate was
incubated with increasing concentrations of black tea extract for 24 hrs and pictures
were taken at 0 hr and 24 hrs. Data represent the mean ± SEM of three
experiments. [****P ≤ 0.0001 compare to control]

G) Effects of natural product extracts and/or their bioactive compounds on
FXIa activity:
Investigations were performed to determine selective inactivation of the serine
protease FXI by the methanol extract of Terminalia chebula fruit. FXI is produced in
the liver as a zymogen and circulates in human plasma in complex with HMWK at an
approximate concentration of 3-7 μg/ml (Bouma, B.N et al. 1977; Roger C. Wiggins
et al. 1977; Thompson, R. E et al. 1977). Thus, we tested the effect of Terminalia
compounds on FXIa activity in fluid phase (Table 5).

56

Figure 42: Effects of black tea aqueous extract on FXIIa-induced HPAEC
migration. HPAECs were seeded in a 96-well plate and incubated overnight at 37
°C to achieve confluence. Then a denuded area was created with a pipette tip. Next,
the plate was incubated with FXIIa (240 nM) in the presence and absence of 10 or
50 mg/ml black tea extract and pictures were taken at 0 hr and 24 hrs (pictures are
shown). Data represent the mean ± SEM of three experiments. [****p ≤ 0.0001
compare to Control, ####p ≤ 0.0001 compare to FXIIa (240 nM)].
We next studied the effects of the methanol extract of T. chebula fruit on FXI
activation on endothelial cell surface. To determine the effect of the methanol
extract of T. chebula fruit on FXIa activity on endothelial cells, HPAEC were treated
with 80 nM HMWK, followed by slow increase in the concentrations of T. chebula
fruit extract in the presence of 40 nM FXI. The activity of FXIa on HPAEC was
assessed by the S2366 substrate hydrolysis. We found that T. chebula fruit extract
blocked FXIa activity on endothelial cells with an IC50 value of 35 mg/ml (Figure 43).
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Figure 43: Effects of Terminalia chebula fruit extract on FXIa activity on
endothelial cells. HPAECs were incubated with HMWK (80 nM) for 1 hr at 37 °C.
Then the cells were incubated with FXI (40 nM) in the presence of increasing
concentrations of T. chebula fruit extract for 1 hr at 37 °C. Next, the cells were
incubated with S2366 (0.5 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed
S2366 was detected at 405 nm. Data represent the mean ± SEM of three
experiments.
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Table 5: Summary of effects of Terminalia compounds on plasma kallikrein, FXIIa,
FXIa and rPRCP
Terminalia Compounds

Inhibitory % at 300 µM
Kallikrein
FXIIa
FXIa rPRCP

Structure

Arjunglucoside II

NE

52

NE

NE

Arjunic acid

NE

NE

NE

NE

Terminolic acid

NE

NE

NE

NE

Arjungenin

NE

NE

NE

NE

Arjunglucoside I

NE

NE

NE

NE

59

Chebuloside II

NE

NE

30

NE

Arjunolic acid

NE

NE

NE

NE

Corilagin

NE

NE

30

NE

Gallic acid

NE

NE

45

NE

Gallic acid methyl ester

NE

NE

NE

NE

Shikimic acid

NE

NE

NE

NE

Ellagic acid

NE

NE

NE

NE

60

Chebulagic acid

NE

NE

25

NE

Chebulinic acid

NE

NE

50

NE

NE

NE

45

NE

NE

NE

52

NE

NE

NE

NE

NE

2, 3, 6-tri-O-galloyl-D-Glucose

1, 2, 3, 6-tetra-Ogalloyl--D-Glucose

1,2,3,4,6-penta-Ogalloyl--D-Glucose

NE: no effect
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Table 6: Summary of effects of red yeast rice compounds on plasma kallikrein,
FXIIa, FXIa and rPRCP

RYR compounds

Inhibitory % at 300 µM
Kallikrein FXIIa FXIa rPRCP

Structure

(R)-6-(2-((1S, 2S)2,6-dimethyl-1,2dihydronaphthalen1-yl)ethyl)-5,6dihydro-2H-pyran-2one

α,β-Dehydrodihydro
monacolin K

Dehydromonacolin
K

Dehydromonacolin L

62

NE

NE

NE

25

NE

NE

40

NE

NE

15

NE

NE

NE

NE

15

20

Monacolin K
(Lovastatin)

Dihydromonacolin K

(6R)-6-(2-((1R, 2R,
3S, 6R)-3-hydroxy2,6-dimethyl1,2,3,5,6,7,8,8aoctahydronaphthale
n-1-yl)ethyl)-5,6dihydro-2H-pyran-2one

Monascusazaphilol

63

NE

NE

NE

NE

NE

NE

55

NE

NE

NE

NE

32

NE

15

NE

NE

2H-Pyran-2-one, 6[2-(1,2-dihydro-2,6dimethyl-1naphthalenyl)ethyl]
tetrahydro-4hydroxy-, [4R-[4α,
6β(1S*,2S*)]]

(2S)-(3R, 4S, 6S ,
7R, 8S)-4,6dihydroxy-3,7dimethyl-8-(2-((R)-6oxo-3,6-dihydro-2Hpyran-2-yl)ethyl)1,2,3,4,6,7,8,8aoctahydronaphthale
n-1-yl 2methylbutanoate

Hydroxy-3,5dihydromonacolin L

(4R, 6R)-4-hydroxy6-(2((1R,2R,3R,6R)-3hydroxy-2,6dimethyl1,2,3,5,6,7,8,8aoctahydronaphthale
n-1yl)ethyl)tetrahydro2H-pyran-2-one

β, δ-dihydroxy-7-[l
,2,3,5,6,7,8,8aoctahydro-3,5dihydroxy-2,6dimethyl8-(2-methylbutyryloxy)naphthalen- 1 -yl]heptanoic acid δlactone

64

NE

NE

15

35

NE

NE

15

NE

NE

NE

15

25

NE

20

NE

NE

NE

25

NE

NE

Dihydromonacolin L

1Naphthalenepropan
oic acid, 1,2,4a,5,6,
7,8,8a-octahydro-2,
6-dimethyl-(1S,2S,
4aR,6R,8aS)-

(9S,10R,11E,13R)9,10,13trihytroxyoctadec11-enoic acid

NE

15

40

NE

NE

35

55

NE

NE

NE

NE

NE

NE: no effect

RYR extract has a cholesterol lowering properties. It is composed of 13
natural statins, unsaturated fatty acids, ergosterol, amino acids, flavonoids, alkaloid
and trace element. The previous studies have indicated the lipid lowering and antiinflammatory properties of xuezhikang, a commercial RYR extract preparation
(Heber D et al. 1999). We tested the effects of RYR extract as well as its pure
compounds on plasma kallikrein, FXIa, FXIIa and rPRCP. The results indicated that
RYR extract has no effects on plasma kallikrein (Figure 44), FXIIa (Figure 45) and
FXIa, with a minor inhibitory effect on rPRCP 30% inhibition at 200 mg/ml (Figure
46).
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Figure 44: Effect of red yeast rice extract on plasma kallikrein activity.
Increasing concentrations of RYR extract was incubated with Kallikrein (2 nM) and
S2302 (0.4 mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was
detected at 405 nm. Data represent the mean ± SEM of three experiments.

Figure 45: Effect of red yeast rice extract on FXIIa activity. Increasing
concentrations of RYR extract were incubated with FXIIa (17 nM) and S2302 (0.4
mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2302 was detected at 405
nm. Data represent the mean ± SEM of three experiments.

66

% r P R C P a c tiv ity

100

75

50

25

0
0

50

100

150

200

R e d y e a s t r i c e e x t r a c t ( m g /m l )

Figure 46: Effect of red yeast rice extract on rPRCP activity. Increasing
concentrations of RYR extract was incubated with rPRCP (30 µg/ml) and the
substrate APpNA (0.3 mM) for 1 hr at 37 °C. The absorbance of paranitronilide was
detected at 405 nm. Data represent the mean ± SEM of three experiments.

During the course of screening of the RYR pure compounds on kallikrein, FXIa
and FXIIa, three of them showed inhibitory effects on FXIa (Table 6). Accordingly,
we decided to determine whether their effects are concentration dependent.
The results indicated that dihydromonacolin K (Figure 47, Tables 6 & 9), 1naphthalenepropanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,
6R,8aS) (Figure 47, Tables 6 & 9) and α,β-dehydrodihydromonacolin K (Figure 47,
Tables 6 & 9) have inhibitory effects with IC50 values of 260, 270 & 400, respectively.
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Figure 47: Effects of RYR active compounds on FXIa activity. Increasing
concentration of the RYR pure compounds (1 µM to 1000 µM) were incubated with 2
nM of FXIa and 0.291 mM of the substrate (Glu-Pro-Arg-p-Nitroanilide, S2366) in
HEPES buffer for 1 hr at 37 ºC. Then the substrate hydrolysis was assessed
spectrophotometrically at 405 nm. Data represent the mean ± SEM of three
experiments.
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Figure 48: Effects of RYR active compounds on FXIa activity on endothelial
cells. HPAECs were incubated with HMWK (80 nM) for 1 hr at 37 °C. Then the cells
were incubated with FXI (40 nM) in the presence of increasing concentrations of
RYR compounds for 1 hr at 37 °C. Next, the cells were incubated with S2366 (0.5
mM) for 1 hr at 37 °C. The absorbance of hydrolyzed S2366 was detected at 405
nm. Data represent the mean ± SEM of three experiments.

69

IV-DISCUSSION
Investigations revealed for first time the effects of some important natural
product extracts on kallikrein-kinin system. The major findings of this study are: (1)
methanol extracts of different Terminalia species (T. arjuna fruit, T. arjuna bark, T.
bellirica fruit, T. brownii bark and T. chebula) inhibited plasma kallikrein, PK
activation on endothelial cell surfaces, FXIIa and rPRCP activities; (2) methanol
extract of T. chebula fruit abolished the activation of FXI to FXIa on endothelial cell
surfaces; (3) arjunoglucoside II and arjunic acid from Terminalias inhibited FXIIa
activity; (4) aqueous extract of black tea inhibited the activities of plasma kallikrein,
FXIIa, rPRCP and FXIIa-induced endothelial cell migration; (5) dihydromonacolin K,
1-naphthalenepropanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,
6R,8aS) and α,β-dehydrodihydromonacolin K from red yeast rice inhibited the
activity of FXIa.
Plasma kallikrein is implicated in the pathological processes inflammation
and HAE through different systems plasma Kallikrein-Kinin, complement and
fibrinolytic systems. These systems are regulated in plasma mainly by C1-INH. C1INH inhibits FXIIa and kallikrein (Pixley et al., 1985). In addition, C1-INH inhibits the
activation of the complements C1r and C1s in the complement system. In HAE,
mutations of C1-INH gene cause a reduction in the levels of functional C1-INH
protein, leading to an overproduction of BK.
Plasma kallikrein hydrolyzes HMWK to release the potent proinflammatory
peptide BK. BK mediates its effects mainly via B2R (Leeb-Lundberg LM et al., 2005;
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Marceau F et al., 1998). The binding of BK to B2R on endothelial cells results in an
increase in the intracellular Ca2+ levels and subsequent production of endogenous
vasodilators NO and PGI2 causing an increase in vascular permeability and edema
(Zhao et al., 2001; Hong, 1980; Palmer et al.1987). The deficiency of C1-INH results
in reduced levels of plasma PK and HMWK (Gigli I et al., 1975; Trumpi-Kalshoven et
al., 1978; Gallimore et al., 1979). BK is responsible for most of the symptoms
associated with the edema in patients with acute HAE attacks (Nussberger et al.
2002). Undoubtedly, BK is deeply implicated in the pathophysiology and clinical
manifestations of HAE.
We have screened several natural plant extracts listed in (Table 4) for their
effects on FXIIa, kallikrein and rPRCP in the liberation of BK from HMWK that could
be used for the purpose of HAE management. These natural products were selected
based on their anti-inflammatory and cardiovascular effects reported in the literature
as well as their safety and availability. Using a selected concentration 200 mg/ml, we
explored the inhibitory effects of those extracts and accordingly continued our study
on the extracts that showed the most promising effects. Methanol extracts of
different species of Terminalia were tested for their inhibitory effects on plasma
kallikrein activity in fluid phase using 200 mg/ml of each. T. arjuna fruit, T. bellirica
fruit, T. brownii bark and T. chebula fruit significantly blocked the proteolytic activity
of plasma kallikrein activity in fluid phase by 45%, 65%, 45% and 85%, respectively
(Figure 5). In contrast, T. arjuna bark extract did not show a significant inhibitory
effect on plasma kallikrein at the same concentration (Figure 5). The aqueous
extract of black tea was selected for study for two main reasons, its significant antiinflammatory effect (Chatterjee P et al. 2012) and the high consumption of black tea,
in which it is considered one of the most common beverages worldwide (Graham
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H.N et al. 1991; Monika Mueller. 2010). At 200 mg/ml, it was indicated that black tea
aqueous extract in fluid phase significantly inhibited the hydrolysis of S2302 by
plasma kallikrein by 55%. At the same selected concentration, methanol extracts of
some other natural product extracts also significantly inhibited plasma kallikrein
activity; black pepper (35%) and cardamom (30%), cayenne pepper (15%), clove
(15%), cumin (25%), poppy seed (50%), dill (20%), garlic (15%), ginger (17%) and
rosemary (17%) (Figure 5). The methanol extract of red yeast rice was also tested
on plasma kallikrein activity and showed no effect (Figure 5). Initial studies showed
that the methanol extracts of Terminalia species and the aqueous extract of black
tea exhibited the highest inhibitory effects toward plasma kallikrein activity.
In the traditional Ayurvedic medicines, T. arjuna bark was used for different
purposes including antidyslipidemic, anti-inflammatory, antioxidant and maintaining
heart functions by strengthening and improving cardiac muscles (Chander R et al,
2004; Maulik SK et al. 2012). Although T. arjuna bark has no effects on kallikrein at
highest concentrations, studies were done to compare it with other species.
The results indicated that T. arjuna fruit, T. arjuna bark, T. bellirica fruit, T.
brownii bark and T. chebula fruit inhibited plasma kallikrein activity with IC50 values of
220, 280, 65, 240 and 30 mg/ml, respectively (Figures 6, 7, 8, 9 & 10). T. arjuna
bark showed stimulatory effects at lower concentrations, but at higher concentrations
blocked plasma kallikrein activity. Among all the species tested, T. chebula fruit has
shown the highest inhibitory effect on plasma kallikrein activity. We also determined
the effects of Terminalias pure compounds. Compounds isolated from T. bellirica
fruit were chebulagic acid, gallic acid, gallic acid methyl ester, (1, 2, 3, 6-tetra-Ogalloyl--D-Glucose) and (1,2,3,4,6-penta-O-galloyl--D-Glucose). Compounds
isolated from T. chebula fruit were arjunglucoside II, arjunic acid, terminolic acid,
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arjungenin, arjunglucoside I, chebuloside II, arjunolic acid, shikimic acid and ellagic
acid. Three compounds were isolated from both T. bellirica fruit and T. chebula fruit
were corilagin, chebulinic acid and (2, 3, 6-tri-O-galloyl--D-Glucose). At 300 μM, all
tested compounds showed no inhibitory effects on plasma kallirein in fluid phase.
Some compounds instead showed minor stimulatory effects on plasma kallikrein
compared to the control. These include arjunolic acid and ellagic acid (from T.
chebula fruit), 1,2,3,4,6-penta-O-galloyl--D-Glucose and gallic acid methyl ester
(from T. bellerica fruit) with stimulatory effects of 19%, 26%, 16% and 13%,
respectively. Ellagic acid showed the highest stimulatory effect on plasma kallikrein
activity in fluid phase. Ellagic acid was also isolated from T. bellerica fruit (Pfundstein
B et al. 2010). In addition, gallic acid and its derivatives such as (1,2,3,4,6-penta-Ogalloyl--D-glucose) are predominant polyphenols in the methanol extract of T.
bellerica fruit compare to T. chebula fruit. The greater presence of compounds with
minor stimulatory effects on plasma kallikrein in T. bellerica than T. chebula probably
explains the lower inhibitory effect of T. bellerica (IC50 value of 65 mg/ml) compare to
T. chebula (IC50 value of 30 mg/ml) through their weak stimulatory effects. The
presence of these stimulatory compounds in very low concentrations in the extracts
probably allowed the inhibitory effects of the extracts to outweigh their minor plasma
kallikrein stimulatory effects. The inhibitory effects exhibited by Terminalias extracts
versus the isolated compounds could be due to the positive interactions between the
components, in which the pharmacodynamic synergy might be crucial for their
effects. The aqueous extract of black tea also blocked the activity of plasma
kallikrein with an IC50 value of 220 mg/ml (Figure 11).
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Table 7: Summary of effects of natural product extracts on Kallikrein formed on
HPAEC

Inhibition of Kallikrein formed on
HPAEC surface

Plant extracts

IC50 values (mg/mL)

Terminalia

Anise

90

Basil

100

Black Pepper

500

Cinnamon

NE

Coriander

250

Fennel

NE

Mentha

300

Poppy seed

300

Thyme

175

Black tea

400

T. arjuna fruit

20

T. arjuna bark

160

T. bellirica fruit

20

T. brownii bark

80

T. chebula fruit

15

Red yeast rice

NE

NE: no effect
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Table 8: Summary of effects of natural product extracts on Kallikrein, FXIIa and
rPRCP

% kallikrein
inhibition

% rPRCP
Inhibition

(200 mg/ml)

(200 mg/ml)

Anise

NE

30

20

Basil

NE

50

55

Black Pepper

35

30

NE

Cinnamon

NE

70

65

Coriander

NE

25

NE

Fennel

NE

52

NE

Mentha

NE

45

30

Poppy seed

50

22

NE

Thyme

NE

23

NE

Black tea

55

60

80

T. arjuna fruit

45

65

55

T. arjuna bark

NE

NE

55

T. bellirica fruit

65

NE

90

T. brownii bark

45

NE

20

T. chebula fruit

85

80

98

NE

NE

NE

Plant extract

Terminalia

Red yeast rice

% FXIIa
Inhibition
(200 mg/ml)

NE: no effect
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The major black tea compounds included epigallocatechin gallate (EGCG),
epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), caffeine and
quercetin, which showed no inhibitory effects on plasma kallikrein activity (Figure
32). We have also tested black tea extract with more than 80% theaflavins
(theaflavin and theaflavin gallates) and also showed no effect. In conclusion, our
data suggest that Terminalias and black tea extracts have specific effects on the
components of KKS. In addition, our data indicate the presence of uncharacterized
inhibitor(s) of kallikrein. All Terminalias methanol extracts (except T. arjuna bark) as
well as the black tea aqueous extract inhibited plasma kallikrein activity. The results
indicated that T. chebula fruit extract showed the highest inhibitory effect on plasma
kallikrein activity with an IC50 value of 30 mg/ml (Figure 10).
Plasma kallikrein is produced and released from the liver as a zymogen
(prekallikrein) that is circulated in plasma as a complex with HMWK, which functions
as a cofactor for the activation PK (Kaplan AP et al. 2003). The assembly of the
HMWK-PK complex on endothelial cell surfaces resulted in a rapidly activation of PK
to kallikrein. This activation is mediated by the interaction of HMWK with a complex
of several proteins including cytokeratin 1, gC1qR as well as urokinase plasminogen
activator receptor (uPAR) (Joseph K et al. 1999; Mahdi F et al. 2001).
The results indicated that the methanol extracts of the Terminalia species and the
aqueous extract of black tea blocked the activity of plasma kallikrein in fluid phase.
Next, we determined the pharmacological effects of the methanol extracts of the
Terminalia species and the aqueous extract of black tea on the formation of kallikrein
on endothelial cells (HPAEC). The investigations indicated that T. arjuna fruit, T.
arjuna bark, T. bellirica fruit, T. brownii bark and T. chebula fruit inhibited the
kallikrein produced on HPAEC with IC50 values of 20 and 160, 20, 80 and 15 mg/ml,
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respectively (Figures 12, 13, 14, 15 & 16). We also indicated that the aqueous
extract of black tea blocked kallikrein formed on endothelial cells (HPAEC) with an
IC50 value of 400 mg/ml (Figure 19). The inhibitory effects of these extracts might be
due to either directly blocking effects on the activity of kallikrein produced by the
activation of the HMWK-PK complex on HPAEC or due to interference with the
assembly of this complex on HPAEC surfaces. In conclusion, all Terminalias
methanol extracts as well as the black tea aqueous extract abolished kallikrein
generation on HPAEC surfaces.
In HAE patients, the reduction in the C1-INH levels causes overproduction of
FXIIa to initiate a contact system leading to a local production of BK (Moreau ME et
al. 2005; Weiss R et al. 1986). Thus, studies indicated that FXIIa might be implicated
in HAE disease either through converting PK to kallikrein or activating of its
autoactivation cycle producing more FXIIa, and ultimately up-regulates kallikrein
generation (Kaplan AP et al. 2003; Fernando LP et al. 2003). It was reported that
PRCP and Heat Shock Protein-90 (HSP90) could also directly activate PK to
kallikrein on endothelial cells independently from FXII-activation pathway (ShariatMadar et al. 2002; Joseph K et al. 2009). Thus, PRCP-dependent PK activation
might be considered as an additional BK-forming mechanism leading to additional
NO and PGI2 production. Several stimuli were found to activate PK to kallikrein on
endothelial cells such as FXIIa and PRCP, we determined whether Terminalias
methanol extracts as well as the black tea aqueous extract could inhibit FXIIa and
rPRCP activities in fluid phases. Our results indicated that T. chebula fruit also
showed the highest inhibitory effect on FXIIa activity in fluid phase with IC50 value of
30 mg/ml compared to the effects of T. arjuna fruit, T. arjuna bark and T. bellirica fruit
which blocked FXIIa activity with IC50 values of 190, 190 and 50 mg/ml, respectively
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(Figures 20, 21, 22 & 23). The results also indicated that T. brownii bark showed the
weakest inhibitory effect with only 27% reduction in the activity of FXIIa at
concentration up to 300 mg/ml (Figure 24). Investigation of the Terminalias pure
compounds revealed that the triterpene glucoside, arjunoglucoside II and an
aglycone terpenoid, arjunic acid blocked the activity of FXIIa activity with IC50 values
of 370 and 780 µM, respectively (Figures 26 & 27). The study also indicated that
ellagic acid and (1,2,3,4,6-penta-O-galloyl--D-glucose) increased FXIIa activity by
25% and 23%, respectively. Previously, it was reported that ellagic acid could
activate FXII (Hageman factor) to FXIIa in a mechanism similar to the negatively
charged surfaces such as glass or kaolin (Ratnoff OD and Saito H. 1982) and can be
used as a model to induce Hageman factor activation experimentally (Ratnoff OD.
1981). The low concentration of ellagic acid among mixture of compounds in
Terminalias extract was not enough to interfere with extract inhibitory properties
(Table 5).
On the effect of the aqueous extract of black tea on FXIIa in fluid phase, we
found that the aqueous extract of black tea also blocked the activity of FXIIa in a
dose-dependent manner with an IC50 value of 27 mg/ml (Figure 25). Additionally,
we also found that black tea pure compounds including epigallocatechin gallate
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC),
caffeine and quercetin showed no inhibitory effects on FXIIa activity (Figure 32). The
inhibitory effect of the aqueous extract of black tea on FXIIa-induced HPAEC
migration was assessed. To determined which concentrations of black tea aqueous
extract can inhibit HPAEC migration, a dose response was performed with
increasing concentrations of tea 5-100 mg/ml and indicated that the aqueous extract
of black tea significantly inhbited HPAEC migration only at concentration up to 100
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mg/ml (Figure 41). Using the highest concentration of FXII 240 nM to induce
HPAEC migration, it was found that the aqueous extract of black tea at 50 mg/ml
was significantly inhibited FXIIa-induce HPAEC migration, confirming the inhibitory
effect of black tea aqueous extract on FXIIa activity (Figure 42). On the effect of
extracts on rPRCP activity, studies indicated that T. arjuna fruit, T. chebula fruit and
T. brownii bark extracts blocked rPRCP activity with an IC50 values of 150, 120 and
280 mg/ml, respectively (Figures 28, 29 & 30). T. arjuna bark and T. bellirica fruit
did not block rPRCP activtity. Furthermore, all Terminalia pure compounds showed
no effects on rPRCP activity. While black tea aqueous extract blocked rPRCP
activity with IC50 values of 160 mg/ml, pure compounds epigallocatechin gallate
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC),
caffeine and quercetin showed no inhibitory effects on rPRCP activity in fluid phase
(Figures 31 & 32). In addition to the evidence presented above, which
demonstrates the inhibitory effects of the methanol extracts of Terminalias and the
aqueous extract of black tea on kallikrein activity, we were interested in determining
whether Terminalias and black tea aqueous extracts are capable of reducing cell
viability. While T. arjuna fruit showed no significant effects on HPAECs viability
(Figure 33), T. arjuna bark significantly reduced HPAECs viability by 40% at
concentrations as low as 30 mg/ml using cell survival ratio using the MTT assay
(Figure 34). A previous study indicated that T. arjuna fruit extract was capable of
maintaining hepatocytes viability and reducing cadmium-induced hepatic oxidative
stress using the MTT assay (J. Ghosh et al. 2010). In the present study, we
confirmed the capability of T. arjuna fruit extract to maintain cell viability of HPAECs
using the MTT assay. Our finding also confirmed that a component of T. arjuna fruit
is an inhibitor of kallikrein. On the other hand, T. bellirica fruit and T. brownii bark
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were significantly toxic to HPAECs in which T. bellirica fruit exhibited a cytotoxic
effect in a dose-dependent manner and T. brownii bark reduced HPAECs viability at
concentrations as low as 20 mg/ml by approximately 40% indicating its highly toxic
effect on endothelial cells (Figures 35 & 36). Interestingly, T. chebula fruit extract
exhibited no effects on HPAECs viability at concentrations up to 500 mg/ml (Figure
37). A previous study reported that T. chebula fruit extract significantly decreased rat
pheochromocytoma cells (PC12) death induced by oxygen-glucose deprivation
followed by reoxygenation (OGD-R), H2O2 and LPS suggesting a protective effect of
T. chebula fruit extract through its antioxidant and antiinflammatory properties (Gaire
BP et al. 2013). In this study, we confirmed that T. chebula fruit extract was capable
of maintaining cell viability of HPAECs using the MTT assay (Figure 37). Among all
Terminalias, the results of T. chebula fruit extract suggested that the inhibitory effect
of the methanol extract of T. chebula fruit on kallikrein produced on endothelial cell
surfaces is not due to a direct cytotoxic effect to endothelial cells.
While arjunoglucoside II significantly deceased the viability of cells only at
high dose up to 1 mM (Figure 38), arjunic acid reduced HPAEC viability by 20% at
concentration 300 μM and by approximately 100% at 1 mM (Figure 39). The
investigation revealed that black tea aqueous extract has no significant effect on
HPAECs viability after 1 hr treatment. On the contrary, HPAECs viability was
significantly reduced by approximately 80% at concentrations starting from 100
mg/ml after 24 hours treatment (Figure 40). Taken all together, our data indicated
that the extracts of T. chebula fruit and T. arjuna fruit were capable of inhibiting kiningenerating enzymes and did not contain cytotoxic factors for HPAEC at the effective
concentrations.
In order to further characterize the selectivity of the most active extract T.
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chebula fruit extract to plasma kallikrein and also due to the structural similarities
between plasma kallikrein and FXIa, we have determined the ability of T. chebula
fruit extract to inhibit the activation of FXI to FXIa on HPAEC surfaces. The study
indicated that T. chebula fruit extract blocked FXIa activity on HPAECs with an IC50
value of 35 mg/ml (Figure 43). We also tested the effects of Terminalias compounds
on FXIa activity in fluid phase.
Table 9: Summary of the pure secondary metabolites identified in our study
Plant
source

Compounds

Structure

Inhibitory effects with IC50 (µM)
Kallikrein FXIIa FXIa rPRCP

NE

370

NE

NE

NE

780

NE

NE

α,βDehydrodihydromon
acolin K

NE

NE

400

NE

Dihydromonacolin K

NE

NE

260

NE

1Naphthalenepropan
oic acid, 1,2,4a,5,6,
7,8,8a-octahydro-2,
6-dimethyl-(1S,2S,
4aR,6R,8aS)

NE

NE

270

NE

Arjunoglucoside II

Terminalia

Ajunic acid

Red yeast
rice
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NE: no effect
The results indicated that chebuloside II, corilagin, gallic acid, chebulagic
acid, chebulinic acid, (2, 3, 6-tri-O-galloyl--D-Glucose) and (1, 2, 3, 6-tetra-Ogalloyl--D-glucose) blocked FXIa activity by 30%, 30%, 45%, 25%, 50%, 45% and
52% at 300 μM, respectively (Table 6). In conclusion, our data demonstrated that T.
chebula fruit also have an affinity for FXIa. Thus, this extract might be used safely as
a supplement to improve the anticoagulant effects.
The extract of RYR had a cholesterol lowering effect, and different RYR
preparations are commerciallly available. The lipid lowering and anti-inflammatory
properties of xuezhikang, a commercial RYR extract preparation, were confirmed
(Heber D et al. 1999). The extract of RYR had pharmacologically active constituents
including thirteen natural statins. Thus, we have tested the effects of RYR extract as
well as its isolated pure compounds on all enzymes of interest that are involved in
BK liberation. We determined for the first time that RYR extract had a stimulatory
effect on plasma kallikrein up to 20% at 10 mg/ml and exceeded 43% at 300 mg/ml.
In a previous study, it was indicated that lovastatin, also known as monacolin K
(RYR component) upregulates the expression of cardioprotective B2R in endothelial
cells (Liesmaa I et al. 2007). Our findings, explored the impact of RYR extract on the
Kallikrein-Kinin system through plasm kallikrein, the major liberator of BK from
HMWK in human body. We also indicated that RYR extract has no effects on FXIIa
and FXIa, whereas it has a minor inhibitory effect on rPRCP 30% inhibition at 200
mg/ml (Figures 44, 45 & 46). The results indicated that RYR pure compounds
showed no effects on plasma kallikrein, FXIIa and rPRCP. Interestingly, among all
RYR compounds, three of them named dihydromonacolin K, [1-Naphthalene
propanoic acid 1,2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,6R,8aS)] and
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α,β-dehydrodihydromonacolin K showed inhibitory effects on FXIa activity in fluid
phase by 55%, 55% and 40% at 300 μM, respectively (Table 6). Thus, we determined
their IC50 values and found that dihydromonacolin K, 1-naphthalenepropanoic acid 1,
2,4a,5,6,7,8,8a-octahydro-2,6-dimethyl-(1S,2S,4aR,6R,8aS) and α,βdehydrodihydromonacolin K blocked FXIa activity in fluid phase with IC50 values of
260, 270 & 400, respectively (Figures 47 & 9). Recently, FXIa inhibitor named BMS262084 demonstrated antithrombotic effect in rat models of arterial and venous
thrombosis, suggesting FXIa an alternative anticoagulation target (Schumacher A et
al. 2007). In conclusion, it was reported that RYR extract consumption is associated
with an edema symptoms. Thus, our findings suggested that RYR extract is probably
implicated in the appearance of edema symptoms through a plasma Kallikrein-Kinin
mediated mechanism. In addition, we indicated novel FXIa inhibitors that could be
used as a lead compounds for identifying more potent FXIa inhibitors that might be
used for thrombosis management purposes.

In summary, the effects of all screened natural product extracts on plasma
kallikrein, kallikrein formed on HPAEC, FXIIa, FXIa and rPRCP were summarized in
Tables 7 & 8. The results indicated that among all screened natural product extracts,
the methanol extract of T. chebula fruit and the aqueous extract black tea were
indicated as the most promising extracts to develop inhibitors of plasma kallikrein
and FXIIa activities. The results also suggested that the methanol extract of T.
chebula fruit could be used as natural supplement for HAE as well as thrombosis
managements. Additionally, five inhibitors were identified as pure inhibitors from our
study. Two were isolated from T. chebula extract showing inhibitory effects on FXIIa
activity and three were isolated from RYR extract showing inhibitory effects on FXIa
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activity. Thus, we suggested that the identified inhibitors in our study (Table 9) could
be used as lead compounds for future chemical modification work to identify more
potent inhibitors.
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